Lymphoma (DLBCL & Follicular)

Diffuse large B-cell lymphoma and follicular lymphoma have seen major advances with CAR-T cell therapies, bispecific antibodies targeting CD20×CD3, and next-generation anti-CD20 agents. Polatuzumab vedotin and loncastuximab tesirine offer ADC options for relapsed disease.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Lymphoma (DLBCL & Follicular)

• Rituximab (Rituxan) — Monoclonal Antibody
• Obinutuzumab (Gazyva) — Monoclonal Antibody
• Axicabtagene ciloleucel (Yescarta) — Other
• Tisagenlecleucel (Kymriah) — Other
• Brexucabtagene autoleucel (Tecartus) — Other
• Lisocabtagene maraleucel (Breyanzi) — Other
• Epcoritamab (Epkinly) — Other
• Glofitamab (Columvi) — Other
• Mosunetuzumab (Lunsumio) — Monoclonal Antibody
• Loncastuximab tesirine-lpyl (Zynlonta) — Antibody-Drug Conjugate
• Polatuzumab vedotin (Polivy) — Antibody-Drug Conjugate
• Tafasitamab (Monjuvi) — Monoclonal Antibody
• Zanubrutinib (Brukinsa) — BTK Inhibitor
• Ibrutinib (Imbruvica) — Tyrosine Kinase Inhibitor